GlassScriptPhysician profile
Elise V Maro
NPI 1598583718
$3,126.07
in general payments reported to CMS, 2019-2025
18 companies · $3,126 in 2025
The $3,126 reported for 2025 was more than what 97% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $3,126.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,126.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,126.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $765.99 | 2025 | Tremfya, Stelara, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $451.99 | 2025 | Entyvio, Eohilia |
| Abbvie INC. | $360.33 | 2025 | |
| Madrigal Pharmaceuticals | $262.88 | 2025 | Rezdiffra |
| Pfizer INC. | $181.18 | 2025 | |
| Phathom Pharmaceuticals, INC. | $166.36 | 2025 | Voquezna |
| Genzyme Corporation | $141.17 | 2025 | |
| Vivus LLC | $137.94 | 2025 | Pancreaze, Qsymia |
| Ardelyx, INC. | $133.17 | 2025 | Ibsrela |
| Aimmune Therapeutics, INC. | $114.22 | 2025 | Zenpep |
| Qol Medical, LLC | $86.58 | 2025 | Sucraid |
| Ferring Pharmaceuticals INC. | $76.48 | 2025 | Rebyota, Clenpiq |
| Regeneron Healthcare Solutions, INC. | $59.75 | 2025 | Dupixent |
| Gilead Sciences, INC. | $57.36 | 2025 | |
| Lilly USA, LLC | $49.63 | 2025 | Omvoh |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $36.96 | 2025 | Relistor, Xifaxan |
| Intercept Pharmaceuticals, INC. | $23.40 | 2025 | |
| Novo Nordisk INC | $20.68 | 2025 | Wegovy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elise Maro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.